Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database. Issue 6 (3rd April 2017)

• Record Type: Journal Article
• Authors: Liu, Guodong; Sterling, Nicholas W.; Kong, Lan; Lewis, Mechelle M.; Mailman, Richard B.; Chen, Honglei; Leslie, Douglas; Huang, Xuemei
• Is Part Of: Movement disorders. Volume 32:Issue 6(2017)
• Page Start: 913
• Page End: 917
• Publication Date: 2017-04-03
• Subjects: Parkinson's disease -- statins -- cholesterol -- large data; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.27006
• Languages: English
• ISSNs: 0885-3185

Abstract

Abstract: Objective: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). Methods: We performed a retrospective case‐control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow‐up window to explore the relationship of statin use with incident PD. Results: Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P < .0001) versus hydrophilic (odds ratio = 1.19, P = .25) statins, statins plus nonstatins (odds ratio = 1.95, P < .0001), and for the initial period after starting statins (<1 year odds ratio = 1.82, 1‐2.5 years odds ratio = 1.75, and ≥2.5 years odds ratio = 1.37; P trend < .0001). Conclusion: The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect. © 2017 International Parkinson and Movement Disorder Society